Abstract
The present invention relates to an isolated CD31+ cell derived from adipose-derived regenerative cells (ADRC's), for use as a medicament. The invention also relates to compositions comprising such cells. In addition, the invention relates to methods for screening for the regenerative capacity of a population of adipose-derived regenerative cells (ADRC's).
Original language | English |
---|---|
IPC | A61K35/16,A61K38/19,A61P15/10 |
Patent number | WO2019193052 (A1) |
Filing date | 10/10/2019 |
Country/Territory | Denmark |
Priority date | 04/04/2018 |
Priority number | DKPA201870194A |
Publication status | Published - 10. Oct 2019 |